Skip to main content
Erschienen in: Clinical Rheumatology 5/2018

07.03.2018 | Original Article

Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults

verfasst von: Latika Gupta, Smriti Chaurasia, Puja Srivastava, Sanjay Dwivedi, Able Lawrence, Ramnath Misra

Erschienen in: Clinical Rheumatology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

We studied the serum levels of B cell survival factors BAFF and APRIL in patients with idiopathic inflammatory myositis (IIM) and their relation with clinical and autoantibodies. Seventy-five patients (51 females and 24 males) with IIM (Bohan and Peter’s criteria 1975) and 25 healthy adults were analyzed for BAFF, APRIL and IL-17 by ELISA, and myositis-specific and associated antibodies (MSA and MAA) using line immunoblot assay. Of the 75 patients, 59 were adults, 42 had Dermatomyositis (DM), and 17 had Polymyositis. Median disease duration was 5 (3–12) months. BAFF levels were higher in IIM than healthy controls [p = 0.001], and in children with jDM than adults [p = 0.026]. BAFF levels were higher in adults with arthritis [p = 0.018], weight loss [p = 0.007], and PAH [p = 0.004]. Among the various MSAs, lowest levels were seen in those with anti-SRP [p = 0.043]. Median follow-up duration was 145 patient years. Twelve patients relapsed, while nine were in drug-free remission. BAFF were similar between these groups. Serum APRIL levels were elevated in limited number of patients with myositis, and the levels did not differ amongst the clinico-serologic phenotypes. IL-17 levels were higher in individuals positive for anti-SRP [p = 0.028]. Serum BAFF levels are elevated in IIM, more so in children. BAFF levels may be useful as biomarker for PAH and arthritis. Anti-SRP positivity is associated with elevated IL-17 levels suggesting role in pathogenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41:22–26CrossRef Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41:22–26CrossRef
2.
Zurück zum Zitat Lundberg IE, Forbess CJ (2008) Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 26:S109–S114PubMed Lundberg IE, Forbess CJ (2008) Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 26:S109–S114PubMed
3.
Zurück zum Zitat Lundberg IE, Miller FW, Tjärnlund A, Bottai M (2016) Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280:39–51CrossRefPubMedPubMedCentral Lundberg IE, Miller FW, Tjärnlund A, Bottai M (2016) Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280:39–51CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60:1160–1172CrossRefPubMed López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60:1160–1172CrossRefPubMed
5.
Zurück zum Zitat Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, Yao Y, Greenberg SA (2010) Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42:576–583CrossRefPubMed Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, Yao Y, Greenberg SA (2010) Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42:576–583CrossRefPubMed
6.
Zurück zum Zitat McIntyre D, Zuckerman NS, Field M, Mehr R, Stott DI (2014) The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies. Eur J Immunol 44:585–596CrossRefPubMed McIntyre D, Zuckerman NS, Field M, Mehr R, Stott DI (2014) The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies. Eur J Immunol 44:585–596CrossRefPubMed
7.
Zurück zum Zitat Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, and the RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324CrossRefPubMedPubMedCentral Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, and the RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O (2015) Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One 10:e0133702CrossRefPubMedPubMedCentral Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O (2015) Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One 10:e0133702CrossRefPubMedPubMedCentral
9.
10.
Zurück zum Zitat Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190:291–292CrossRefPubMed Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190:291–292CrossRefPubMed
11.
Zurück zum Zitat Baek A, Park HJ, Na S-J, Shim DS, Moon J-S, Yang Y, Choi YC (2012) The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 249:96–100CrossRefPubMed Baek A, Park HJ, Na S-J, Shim DS, Moon J-S, Yang Y, Choi YC (2012) The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 249:96–100CrossRefPubMed
12.
Zurück zum Zitat Kryštůfková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J et al (2014) Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 16:454CrossRefPubMedPubMedCentral Kryštůfková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J et al (2014) Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 16:454CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Peng Q-L, Shu X-M, Wang D-X, Wang Y, Lu X, Wang G-C (2014) B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med 8:395–403CrossRefPubMed Peng Q-L, Shu X-M, Wang D-X, Wang Y, Lu X, Wang G-C (2014) B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med 8:395–403CrossRefPubMed
14.
Zurück zum Zitat Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23CrossRefPubMed Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23CrossRefPubMed
15.
Zurück zum Zitat Srivastava P, Dwivedi S, Misra R (2016) Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int 36:935–943CrossRefPubMed Srivastava P, Dwivedi S, Misra R (2016) Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int 36:935–943CrossRefPubMed
16.
Zurück zum Zitat Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54CrossRef Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54CrossRef
17.
Zurück zum Zitat Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, Agematsu K, Yokota S, Koike K (2015) Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol 42:2412–2418CrossRefPubMed Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, Agematsu K, Yokota S, Koike K (2015) Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol 42:2412–2418CrossRefPubMed
18.
Zurück zum Zitat Tournadre A, Miossec P (2009) Chemokines and dendritic cells in inflammatory myopathies. Ann Rheum Dis 68:300–304CrossRefPubMed Tournadre A, Miossec P (2009) Chemokines and dendritic cells in inflammatory myopathies. Ann Rheum Dis 68:300–304CrossRefPubMed
19.
Zurück zum Zitat Tournadre A, Lenief V, Miossec P (2010) Expression of toll-like receptor 3 and toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62:2144–2151PubMed Tournadre A, Lenief V, Miossec P (2010) Expression of toll-like receptor 3 and toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62:2144–2151PubMed
20.
Zurück zum Zitat Hengstman GJD, ter Laak HJ, Vree Egberts WTM, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BGM (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638CrossRefPubMedPubMedCentral Hengstman GJD, ter Laak HJ, Vree Egberts WTM, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BGM (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161–2171CrossRefPubMed Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161–2171CrossRefPubMed
22.
Zurück zum Zitat Chevrel G, Granet C, Miossec P (2005) Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappa B nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 64:1257–1262CrossRefPubMedPubMedCentral Chevrel G, Granet C, Miossec P (2005) Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappa B nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 64:1257–1262CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kocić J, Santibañez JF, Krstić A, Mojsilović S, Dorđević IO, Trivanović D et al (2012) Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2. Biochim Biophys Acta 1823:838–849CrossRefPubMed Kocić J, Santibañez JF, Krstić A, Mojsilović S, Dorđević IO, Trivanović D et al (2012) Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2. Biochim Biophys Acta 1823:838–849CrossRefPubMed
24.
Zurück zum Zitat Kocić J, Santibañez JF, Krstić A, Mojsilović S, Ilić V, Bugarski D (2013) Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase. Int J Biochem Cell Biol 45:464–475CrossRefPubMed Kocić J, Santibañez JF, Krstić A, Mojsilović S, Ilić V, Bugarski D (2013) Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase. Int J Biochem Cell Biol 45:464–475CrossRefPubMed
25.
Zurück zum Zitat Moura RA, Quaresma C, Vieira AR, Gonçalves MJ, Polido-Pereira J, Romão VC et al B-cell phenotype and IgD-CD27-memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PloS One 12:e0182927 Moura RA, Quaresma C, Vieira AR, Gonçalves MJ, Polido-Pereira J, Romão VC et al B-cell phenotype and IgD-CD27-memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PloS One 12:e0182927
26.
Zurück zum Zitat Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J et al (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68:836–843CrossRefPubMed Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J et al (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68:836–843CrossRefPubMed
27.
Zurück zum Zitat Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201CrossRefPubMed Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201CrossRefPubMed
28.
Zurück zum Zitat Gupta L, Ahmed S, Zanwar A (2017) The pathogenesis of scleroderma. Indian J Rheumatol 12:142CrossRef Gupta L, Ahmed S, Zanwar A (2017) The pathogenesis of scleroderma. Indian J Rheumatol 12:142CrossRef
29.
Zurück zum Zitat Campi I, Tosi D, Rossi S, Vannucchi G, Covelli D, Colombo F et al. (2015) B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases. Thyroid Off J Am Thyroid Assoc 25:1043–1049CrossRef Campi I, Tosi D, Rossi S, Vannucchi G, Covelli D, Colombo F et al. (2015) B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases. Thyroid Off J Am Thyroid Assoc 25:1043–1049CrossRef
30.
Zurück zum Zitat López De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS et al (2013) BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol 40:294–302CrossRefPubMed López De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS et al (2013) BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol 40:294–302CrossRefPubMed
31.
Zurück zum Zitat Bassyouni IH, Azab NA, El-Dakrony E-HM, Fawzi MMT, Ghanoum R, Bassyouni RH. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis? Jt Bone Spine Rev Rhum 2011;78:56–61 Bassyouni IH, Azab NA, El-Dakrony E-HM, Fawzi MMT, Ghanoum R, Bassyouni RH. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis? Jt Bone Spine Rev Rhum 2011;78:56–61
Metadaten
Titel
Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults
verfasst von
Latika Gupta
Smriti Chaurasia
Puja Srivastava
Sanjay Dwivedi
Able Lawrence
Ramnath Misra
Publikationsdatum
07.03.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 5/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4046-x

Weitere Artikel der Ausgabe 5/2018

Clinical Rheumatology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.